1Jagannath S,Durie BG,Wolf J,et al.Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma[J].Br J Haematol,2005,129(6):776-783.
2Hussein MA,Wood L,Hsi E,et al.A Phase II trial of pegylated liposomal doxorubicin,vincristine,and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients[J].Cancer,2002,95(10):2160-2168.
3Zervas K,Dimopoulos MA,Hatzicharissi E,et al.Primary treatment of multiple myeloma with thalidomide,vincristine,liposomal doxorubicin and dexamethasone (T-VAD doxil):a phase II multicenter study[J].Ann Oncol,2004,15(1):134-138.
4Richardson PG,Barlogie B,Berenson J,et al.Extended follow-up of a phase II trial in relapsed,refractory multiple myeloma:final time-to-event results from the SUMMIT trial[J].Cancer,2006,106(6):1316-1319.
5Badros A,Gahres N.Bortezomib,thalidomide,and dexamethasone for relapsed multiple myeloma:add it up and wait[J].Clin Adv Hematol Oncol,2005,3(12):916-918.
6Kropff MH,Bisping G,Wenning D,et al.Bortezomib in combination with dexamethasone for relapsed multiple myeloma[J].LeuK Res,2005,29(5):587-590.
7Chanan-Khan A,Miller KC.Velcade,Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma[J].Leuk Lymphoma,2005,46(7):1103-1104.
8Berenson JR,Yang HH,Sadler K,et al.Phase Ⅰ/Ⅱ trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma[J].J Clin Oncol,2006,24(6):937-944.
9Hussein MA.Modifications to therapy for multiple myeloma:pegylated liposomal Doxorubicin in combination with vincristine,reduced-dose dexamethasone,and thalidomide[J].Oncologist,2003,8(Suppl 3):39-45.
10Orlowski RZ,Voorhees PM,Garcia RA,et al.Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies[J].Blood,2005,105(8):3058-3065.
2Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma.: meta-analysis of 30 randomised trials among 3948 patients. Am Oncol, 2000, 11:1427 -1436.
3Wada M, Mizoguchi H, Kuriya S I, et al. Inductiontherapy consisting of alternating cycles of ranimustine,vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma.: a cooperative study in Japan. Br J Haematol, 2000, 109:805-814.
4Petrucci M T, La Verde G, Ribersani M, et al. Intravenous melphalan and dexamethasone followed by lymphoblastoid alpha interferon in higher risk multiple myeloma patient s. Leuk Lymphoma, 2000, 39:131-138.
5Oken M M, Leong T, Lenhard R E, et al. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in t he treatment of patients with multiple myeloma: phase Ⅲ Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer,1999, 86:957-968.
6Wisloff F, Hjort h M, Kassa S, et al. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. Br J Haematol, 1996, 94: 324-332.
